CSIR CIMAP AROMA | Compound Details

Camphor Details

: IUPAC Name

4,7,7-trimethylbicyclo[2.2.1]heptan-3-one

:Chemical Class

Monoterpene

:CAS Registry Number

76-22-2

:Description

:Fragrance Type

Physical and Chemical properties

PUBCHEM ID	2537
Molecular Weight (g/mol)	152.233
Molecular Formula	C10H16O
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	1
Rotatable Bond Count	0
IUPAC Name	4,7,7-trimethylbicyclo[2.2.1]heptan-3-one
Canonical SMILES	CC1(C)C2CCC1(C)C(=O)C2
PUBCHEM IUPAC INCHIKEY	DSSYKIVIOFKYAU-UHFFFAOYSA-N
Solubility Level	3
Vapour Pressure	-0.342

Absorption and Metabolism information

XLOGP3 AA	2.2
CACTVS TPSA	17.1
BBB Level	1
Absorption Level	0
EXT PPB#Prediction	1
AlogP98	2.075
EXT CYP2D6#Prediction	0

Toxicological Information

Mouse Female FDA	Multi-Carcinogen
Mouse Male FDA	Multi-Carcinogen
Rat Female FDA	Single-Carcinogen
Rat Male FDA	Multi-Carcinogen
Ames Prediction	Non-Mutagen
Developmental / Reproductive Toxicity	Toxic
Rat Oral LD50	1.69097 g/kg_body_weight
Ocular Irritancy	Mild
Hepatotoxic#Prediction	0
Effected Human Genes	ESR2,TRPM8,CYP2A6,TRPV3,INTS2,EHHADH,TRPV1,TRPA1,CYP2A13

Ecological Information

Aerobic Biodegradability Prediction	Degradable

Hazard(s) Identification

Physical hazards	not classified
Health hazards	Moderate
Environmental hazards	not classified

About Table Headings

Compound Biological Activity

Serial No.	Cas No	Gene Symbol	Organism	Interaction	Interaction Actions	PubMed Id
1	76-22-2	AR	Homo sapiens	3-benzylidene camphor binds to and results in decreased activity of AR protein	affects^binding\|decreases^activity	15537743
2	76-22-2	ER	Pimephales promelas	3-benzylidene camphor binds to and results in increased activity of ER protein	affects^binding\|increases^activity	18992764
3	76-22-2	ESR1	Homo sapiens	3-benzylidene camphor binds to and results in increased activity of ESR1 protein	affects^binding\|increases^activity	24004914
4	76-22-2	ESR1	Rattus norvegicus	3-benzylidene camphor results in increased expression of ESR1 mRNA	increases^expression	19150460
5	76-22-2	ESR2	Homo sapiens	3-benzylidene camphor binds to ESR2 protein	affects^binding	15147785
6	76-22-2	ESR2	Rattus norvegicus	3-benzylidene camphor results in decreased expression of ESR2 mRNA	decreases^expression	19150460
7	76-22-2	NCOA1	Rattus norvegicus	3-benzylidene camphor affects the expression of NCOA1 mRNA	affects^expression	19150460
8	76-22-2	PGR	Homo sapiens	3-benzylidene camphor binds to and results in decreased activity of PGR protein	affects^binding\|decreases^activity	15537743
9	76-22-2	PGR	Rattus norvegicus	3-benzylidene camphor affects the expression of PGR mRNA	affects^expression	19150460
10	76-22-2	VTG	Pimephales promelas	3-benzylidene camphor results in increased expression of VTG protein	increases^expression	18992764
11	76-22-2	ACHE	Electrophorus electricus	Camphor results in increased activity of ACHE protein	increases^activity	25636489
12	76-22-2	COL1A2	Mus musculus	Camphor analog affects the expression of COL1A2 mRNA	affects^expression	24704097
13	76-22-2	ESR1	Homo sapiens	Camphor binds to and results in increased activity of ESR1 protein	affects^binding\|increases^activity	27633901
14	76-22-2	GABRA1	Homo sapiens	Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]	affects^binding\|increases^activity\|increases^reaction	15588619
15	76-22-2	MPO	Mus musculus	Camphor inhibits the reaction [cinnamic aldehyde results in increased activity of MPO protein]	decreases^reaction\|increases^activity	21466812
16	76-22-2	PGR	Homo sapiens	Camphor binds to and results in decreased activity of PGR protein	affects^binding\|decreases^activity	27633901
17	76-22-2	RUNX2	Mus musculus	Camphor analog affects the expression of RUNX2 mRNA	affects^expression	24704097
18	76-22-2	SPARC	Mus musculus	Camphor analog affects the expression of SPARC mRNA	affects^expression	24704097
19	76-22-2	TRPA1		Camphor binds to and results in decreased activity of TRPA1 protein	affects^binding\|decreases^activity	19845671\|21466812
20	76-22-2	TRPV1	Rattus norvegicus	Lidocaine promotes the reaction [Camphor results in increased activity of TRPV1 protein]	increases^activity\|increases^reaction	18172555
21	76-22-2	TRPV1		Camphor binds to and results in increased activity of TRPV1 protein	affects^binding\|increases^activity	16617338
22	76-22-2	TRPV3	Homo sapiens	Camphor results in increased activity of TRPV3 protein	increases^activity	21353389
23	76-22-2	TRPV3	Homo sapiens	isopentenyl pyrophosphate inhibits the reaction [Camphor results in increased activity of TRPV3 protein]	decreases^reaction\|increases^activity	21353389
24	76-22-2	TRPV3		Camphor binds to and results in increased activity of TRPV3 protein	affects^binding\|increases^activity	16617338
25	76-22-2	CCNB1	Homo sapiens	camphorquinone results in decreased expression of CCNB1 mRNA	decreases^expression	26658076
26	76-22-2	CCNB1	Homo sapiens	camphorquinone results in decreased expression of CCNB1 protein	decreases^expression	26658076
27	76-22-2	CDC25C	Homo sapiens	camphorquinone results in decreased expression of CDC25C mRNA	decreases^expression	26658076
28	76-22-2	CDC25C	Homo sapiens	camphorquinone results in decreased expression of CDC25C protein	decreases^expression	26658076
29	76-22-2	CDK1	Homo sapiens	camphorquinone results in decreased expression of CDK1 mRNA	decreases^expression	26658076
30	76-22-2	CDK1	Homo sapiens	camphorquinone results in decreased expression of CDK1 protein	decreases^expression	26658076
31	76-22-2	CDKN1A	Homo sapiens	Acetylcysteine inhibits the reaction [camphorquinone results in increased expression of CDKN1A protein]	decreases^reaction\|increases^expression	26658076
32	76-22-2	CDKN1A	Homo sapiens	camphorquinone results in increased expression of CDKN1A mRNA	increases^expression	26658076
33	76-22-2	CDKN1A	Homo sapiens	camphorquinone results in increased expression of CDKN1A protein	increases^expression	26658076
34	76-22-2	GADD45A	Homo sapiens	camphorquinone results in increased expression of GADD45A protein	increases^expression	26658076
35	76-22-2	HMOX1	Homo sapiens	Acetylcysteine inhibits the reaction [camphorquinone results in increased expression of HMOX1 protein]	decreases^reaction\|increases^expression	26658076
36	76-22-2	HMOX1	Homo sapiens	camphorquinone results in increased expression of HMOX1 mRNA	increases^expression	26658076
37	76-22-2	HMOX1	Homo sapiens	camphorquinone results in increased expression of HMOX1 protein	increases^expression	26658076
38	76-22-2	PTGS2	Homo sapiens	camphorquinone results in increased expression of PTGS2 mRNA	increases^expression	26658076
39	76-22-2	PTGS2	Homo sapiens	camphorquinone results in increased expression of PTGS2 protein	increases^expression	26658076
40	76-22-2	PTGS2	Homo sapiens	U 0126 inhibits the reaction [camphorquinone results in increased expression of PTGS2 protein]	decreases^reaction\|increases^expression	26658076
41	76-22-2	ABAT	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ABAT mRNA	affects^cotreatment\|increases^expression	25607892
42	76-22-2	ACTN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ACTN1 mRNA	affects^cotreatment\|decreases^expression	25607892
43	76-22-2	ADAM17	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA	affects^cotreatment\|decreases^expression	25607892
44	76-22-2	ADAM17	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA	affects^cotreatment\|increases^expression	25607892
45	76-22-2	AR	Homo sapiens	enzacamene binds to and results in decreased activity of AR protein	affects^binding\|decreases^activity	15537743\|24004914
46	76-22-2	AR	Homo sapiens	enzacamene inhibits the reaction [Metribolone binds to and results in increased activity of AR protein]	affects^binding\|decreases^reaction\|increases^activity	24004914
47	76-22-2	BDNF	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of BDNF mRNA	affects^cotreatment\|decreases^expression	25607892
48	76-22-2	BGLAP	Rattus norvegicus	enzacamene results in increased expression of BGLAP protein	increases^expression	15979666
49	76-22-2	BSN	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of BSN mRNA	affects^cotreatment\|decreases^expression	25607892
50	76-22-2	CACNA1A	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1A mRNA	affects^cotreatment\|increases^expression	25607892
51	76-22-2	CACNA1C	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA1C mRNA	affects^cotreatment\|affects^expression	25607892
52	76-22-2	CACNA1C	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1C mRNA	affects^cotreatment\|decreases^expression	25607892
53	76-22-2	CACNA1D	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA1D mRNA	affects^cotreatment\|increases^expression	25607892
54	76-22-2	CACNA1D	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1D mRNA	affects^cotreatment\|increases^expression	25607892
55	76-22-2	CACNA1E	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1E mRNA	affects^cotreatment\|decreases^expression	25607892
56	76-22-2	CACNA1F	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1F mRNA	affects^cotreatment\|decreases^expression	25607892
57	76-22-2	CACNA1G	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1G mRNA	affects^cotreatment\|decreases^expression	25607892
58	76-22-2	CACNA1G	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA1G mRNA	affects^cotreatment\|increases^expression	25607892
59	76-22-2	CACNA1H	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA1H mRNA	affects^cotreatment\|decreases^expression	25607892
60	76-22-2	CACNA1I	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNA1I mRNA	affects^cotreatment\|decreases^expression	25607892
61	76-22-2	CACNA2D1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D1 mRNA	affects^cotreatment\|increases^expression	25607892
62	76-22-2	CACNA2D1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNA2D1 mRNA	affects^cotreatment\|decreases^expression	25607892
63	76-22-2	CACNA2D2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA	affects^cotreatment\|increases^expression	25607892
64	76-22-2	CACNA2D2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D2 mRNA	affects^cotreatment\|increases^expression	25607892
65	76-22-2	CACNA2D3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA	affects^cotreatment\|affects^expression	25607892
66	76-22-2	CACNA2D3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D3 mRNA	affects^cotreatment\|increases^expression	25607892
67	76-22-2	CACNB1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB1 mRNA	affects^cotreatment\|increases^expression	25607892
68	76-22-2	CACNB2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNB2 mRNA	affects^cotreatment\|decreases^expression	25607892
69	76-22-2	CACNB2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB2 mRNA	affects^cotreatment\|increases^expression	25607892
70	76-22-2	CACNB3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNB3 mRNA	affects^cotreatment\|increases^expression	25607892
71	76-22-2	CACNB3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNB3 mRNA	affects^cotreatment\|increases^expression	25607892
72	76-22-2	CACNG2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNG2 mRNA	affects^cotreatment\|increases^expression	25607892
73	76-22-2	CACNG5	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG5 mRNA	affects^cotreatment\|decreases^expression	25607892
74	76-22-2	CACNG6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CACNG6 mRNA	affects^cotreatment\|decreases^expression	25607892
75	76-22-2	CACNG6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG6 mRNA	affects^cotreatment\|decreases^expression	25607892
76	76-22-2	CACNG8	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CACNG8 mRNA	affects^cotreatment\|decreases^expression	25607892
77	76-22-2	CAMK2B	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CAMK2B mRNA	affects^cotreatment\|increases^expression	25607892
78	76-22-2	CASK	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CASK mRNA	affects^cotreatment\|affects^expression	25607892
79	76-22-2	CASK	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CASK mRNA	affects^cotreatment\|decreases^expression	25607892
80	76-22-2	CCL2	Homo sapiens	enzacamene results in increased expression of CCL2 mRNA	increases^expression	23397585
81	76-22-2	CD44	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CD44 mRNA	affects^cotreatment\|decreases^expression	25607892
82	76-22-2	CD44	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CD44 mRNA	affects^cotreatment\|decreases^expression	25607892
83	76-22-2	CHRDL1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CHRDL1 mRNA	affects^cotreatment\|affects^expression	25607892
84	76-22-2	CNST	Homo sapiens	enzacamene results in increased expression of CNST mRNA	increases^expression	23397585
85	76-22-2	CNTN3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN3 mRNA	affects^cotreatment\|decreases^expression	25607892
86	76-22-2	CNTN4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA	affects^cotreatment\|decreases^expression	25607892
87	76-22-2	COPS2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of COPS2 mRNA	affects^cotreatment\|decreases^expression	25607892
88	76-22-2	CYP11B1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of CYP11B1 mRNA	affects^cotreatment\|decreases^expression	25607892
89	76-22-2	CYP17A1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP17A1 mRNA	affects^cotreatment\|increases^expression	25607892
90	76-22-2	CYP19A1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of CYP19A1 mRNA	affects^cotreatment\|affects^expression	25607892
91	76-22-2	CYP19A1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CYP19A1 mRNA	affects^cotreatment\|increases^expression	25607892
92	76-22-2	DCC	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DCC mRNA	affects^cotreatment\|decreases^expression	25607892
93	76-22-2	DLG1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG1 mRNA	affects^cotreatment\|decreases^expression	25607892
94	76-22-2	DLG4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DLG4 mRNA	affects^cotreatment\|decreases^expression	25607892
95	76-22-2	DLG4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLG4 mRNA	affects^cotreatment\|decreases^expression	25607892
96	76-22-2	DLG4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DLG4 mRNA	affects^cotreatment\|increases^expression	25607892
97	76-22-2	DLGAP3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of DLGAP3 mRNA	affects^cotreatment\|increases^expression	25607892
98	76-22-2	DLGAP3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of DLGAP3 mRNA	affects^cotreatment\|decreases^expression	25607892
99	76-22-2	DNMT3A	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of DNMT3A mRNA	affects^cotreatment\|decreases^expression	25607892
100	76-22-2	DPP6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of DPP6 mRNA	affects^cotreatment\|increases^expression	25607892
101	76-22-2	ECR	Chironomus riparius	enzacamene results in increased expression of ECR mRNA	increases^expression	23591065
102	76-22-2	EGF	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of EGF mRNA	affects^cotreatment\|decreases^expression	25607892
103	76-22-2	ERBB2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA	affects^cotreatment\|decreases^expression	25607892
104	76-22-2	ERBB3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA	affects^cotreatment\|decreases^expression	25607892
105	76-22-2	ERBB3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA	affects^cotreatment\|decreases^expression	25607892
106	76-22-2	ERBB4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of ERBB4 mRNA	affects^cotreatment\|affects^expression	25607892
107	76-22-2	ERBB4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB4 mRNA	affects^cotreatment\|decreases^expression	25607892
108	76-22-2	ERBB4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of ERBB4 mRNA	affects^cotreatment\|increases^expression	25607892
109	76-22-2	ERBB4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB4 mRNA	affects^cotreatment\|decreases^expression	25607892
110	76-22-2	ESR1	Homo sapiens	enzacamene binds to and results in increased activity of ESR1 protein	affects^binding\|increases^activity	16079615\|24004914
111	76-22-2	ESR1	Homo sapiens	enzacamene results in increased activity of ESR1 protein	increases^activity	12765243
112	76-22-2	ESR1	Rattus norvegicus	enzacamene results in decreased expression of ESR1 mRNA	decreases^expression	19150460
113	76-22-2	ESR2	Homo sapiens	enzacamene binds to and results in increased activity of ESR2 protein	affects^binding\|increases^activity	16079615
114	76-22-2	ESR2	Homo sapiens	enzacamene binds to ESR2 protein	affects^binding	15147785
115	76-22-2	ESR2	Homo sapiens	enzacamene results in increased activity of ESR2 protein	increases^activity	12765243
116	76-22-2	FGFR1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR1 mRNA	affects^cotreatment\|decreases^expression	25607892
117	76-22-2	FGFR2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of FGFR2 mRNA	affects^cotreatment\|decreases^expression	25607892
118	76-22-2	FYN	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] affects the expression of FYN mRNA	affects^cotreatment\|affects^expression	25607892
119	76-22-2	GABRA4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRA4 mRNA	affects^cotreatment\|decreases^expression	25607892
120	76-22-2	GABRB1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GABRB1 mRNA	affects^cotreatment\|decreases^expression	25607892
121	76-22-2	GLS	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GLS mRNA	affects^cotreatment\|decreases^expression	25607892
122	76-22-2	GLS	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GLS mRNA	affects^cotreatment\|decreases^expression	25607892
123	76-22-2	GRIA2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA2 mRNA	affects^cotreatment\|decreases^expression	25607892
124	76-22-2	GRIA4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIA4 mRNA	affects^cotreatment\|decreases^expression	25607892
125	76-22-2	GRIA4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIA4 mRNA	affects^cotreatment\|decreases^expression	25607892
126	76-22-2	GRIK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIK2 mRNA	affects^cotreatment\|decreases^expression	25607892
127	76-22-2	GRIK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK2 mRNA	affects^cotreatment\|increases^expression	25607892
128	76-22-2	GRIK4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIK4 mRNA	affects^cotreatment\|decreases^expression	25607892
129	76-22-2	GRIK5	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIK5 mRNA	affects^cotreatment\|increases^expression	25607892
130	76-22-2	GRIN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of GRIN1 mRNA	affects^cotreatment\|increases^expression	25607892
131	76-22-2	GRIN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN1 mRNA	affects^cotreatment\|increases^expression	25607892
132	76-22-2	GRIN2B	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2B mRNA	affects^cotreatment\|decreases^expression	25607892
133	76-22-2	GRIN2C	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN2C mRNA	affects^cotreatment\|decreases^expression	25607892
134	76-22-2	GRIN2D	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA	affects^cotreatment\|decreases^expression	25607892
135	76-22-2	GRIN2D	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN2D mRNA	affects^cotreatment\|increases^expression	25607892
136	76-22-2	GRIN3A	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of GRIN3A mRNA	affects^cotreatment\|decreases^expression	25607892
137	76-22-2	GRIP1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIP1 mRNA	affects^cotreatment\|decreases^expression	25607892
138	76-22-2	HES6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HES6 mRNA	affects^cotreatment\|increases^expression	25607892
139	76-22-2	HR	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of HR mRNA	affects^cotreatment\|decreases^expression	25607892
140	76-22-2	HSD17B10	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of HSD17B10 mRNA	affects^cotreatment\|increases^expression	25607892
141	76-22-2	HSD17B8	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of HSD17B8 mRNA	affects^cotreatment\|decreases^expression	25607892
142	76-22-2	HSD3B6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of HSD3B6 mRNA	affects^cotreatment\|decreases^expression	25607892
143	76-22-2	ID2	Homo sapiens	enzacamene results in decreased expression of ID2 mRNA	decreases^expression	23397585
144	76-22-2	IGF1R	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of IGF1R mRNA	affects^cotreatment\|increases^expression	25607892
145	76-22-2	IGF2R	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of IGF2R mRNA	affects^cotreatment\|decreases^expression	25607892
146	76-22-2	IL1RAPL1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of IL1RAPL1 mRNA	affects^cotreatment\|decreases^expression	25607892
147	76-22-2	ITGB5	Homo sapiens	enzacamene results in decreased expression of ITGB5 mRNA	decreases^expression	23397585
148	76-22-2	JAG1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of JAG1 mRNA	affects^cotreatment\|increases^expression	25607892
149	76-22-2	LIN7A	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of LIN7A mRNA	affects^cotreatment\|increases^expression	25607892
150	76-22-2	MAGI2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MAGI2 mRNA	affects^cotreatment\|decreases^expression	25607892
151	76-22-2	MAGI2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MAGI2 mRNA	affects^cotreatment\|increases^expression	25607892
152	76-22-2	MDGA2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of MDGA2 mRNA	affects^cotreatment\|decreases^expression	25607892
153	76-22-2	MDGA2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MDGA2 mRNA	affects^cotreatment\|increases^expression	25607892
154	76-22-2	MET	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of MET mRNA	affects^cotreatment\|increases^expression	25607892
155	76-22-2	MMP3	Rattus norvegicus	[enzacamene co-treated with octylmethoxycinnamate co-treated with bisphenol A co-treated with butylparaben] results in increased expression of MMP3 mRNA	affects^cotreatment\|increases^expression	25305543
156	76-22-2	NCOA1	Rattus norvegicus	enzacamene results in increased expression of NCOA1 mRNA	increases^expression	19150460
157	76-22-2	NF1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NF1 mRNA	affects^cotreatment\|decreases^expression	25607892
158	76-22-2	NF1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NF1 mRNA	affects^cotreatment\|decreases^expression	25607892
159	76-22-2	NLGN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA	affects^cotreatment\|increases^expression	25607892
160	76-22-2	NLGN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NLGN1 mRNA	affects^cotreatment\|decreases^expression	25607892
161	76-22-2	NLGN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NLGN1 mRNA	affects^cotreatment\|increases^expression	25607892
162	76-22-2	NOTCH2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH2 mRNA	affects^cotreatment\|increases^expression	25607892
163	76-22-2	NOTCH2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH2 mRNA	affects^cotreatment\|decreases^expression	25607892
164	76-22-2	NOTCH4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NOTCH4 mRNA	affects^cotreatment\|increases^expression	25607892
165	76-22-2	NOTCH4	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NOTCH4 mRNA	affects^cotreatment\|decreases^expression	25607892
166	76-22-2	NR3C2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NR3C2 mRNA	affects^cotreatment\|increases^expression	25607892
167	76-22-2	NRCAM	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRCAM mRNA	affects^cotreatment\|increases^expression	25607892
168	76-22-2	NRG1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NRG1 mRNA	affects^cotreatment\|decreases^expression	25607892
169	76-22-2	NRG1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRG1 mRNA	affects^cotreatment\|decreases^expression	25607892
170	76-22-2	NRXN1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN1 mRNA	affects^cotreatment\|increases^expression	25607892
171	76-22-2	NRXN2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NRXN2 mRNA	affects^cotreatment\|increases^expression	25607892
172	76-22-2	NRXN2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NRXN2 mRNA	affects^cotreatment\|decreases^expression	25607892
173	76-22-2	NTRK1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK1 mRNA	affects^cotreatment\|increases^expression	25607892
174	76-22-2	NTRK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of NTRK2 mRNA	affects^cotreatment\|decreases^expression	25607892
175	76-22-2	NTRK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK2 mRNA	affects^cotreatment\|increases^expression	25607892
176	76-22-2	NTRK3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NTRK3 mRNA	affects^cotreatment\|increases^expression	25607892
177	76-22-2	NTRK3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NTRK3 mRNA	affects^cotreatment\|increases^expression	25607892
178	76-22-2	NXPH3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NXPH3 mRNA	affects^cotreatment\|decreases^expression	25607892
179	76-22-2	PGR	Homo sapiens	enzacamene binds to and results in decreased activity of PGR protein	affects^binding\|decreases^activity	15537743
180	76-22-2	PGR	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PGR mRNA	affects^cotreatment\|decreases^expression	25607892
181	76-22-2	PGR	Rattus norvegicus	enzacamene affects the expression of PGR mRNA	affects^expression	19150460
182	76-22-2	PRKN	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA	affects^cotreatment\|decreases^expression	25607892
183	76-22-2	PRKN	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of PRKN mRNA	affects^cotreatment\|decreases^expression	25607892
184	76-22-2	RELN	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of RELN mRNA	affects^cotreatment\|decreases^expression	25607892
185	76-22-2	ROBO1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ROBO1 mRNA	affects^cotreatment\|decreases^expression	25607892
186	76-22-2	SHANK1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SHANK1 mRNA	affects^cotreatment\|increases^expression	25607892
187	76-22-2	SHANK1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK1 mRNA	affects^cotreatment\|increases^expression	25607892
188	76-22-2	SHANK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA	affects^cotreatment\|decreases^expression	25607892
189	76-22-2	SHANK2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SHANK2 mRNA	affects^cotreatment\|decreases^expression	25607892
190	76-22-2	SHANK3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK3 mRNA	affects^cotreatment\|increases^expression	25607892
191	76-22-2	SLC17A7	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC17A7 mRNA	affects^cotreatment\|increases^expression	25607892
192	76-22-2	SLC1A1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A1 mRNA	affects^cotreatment\|increases^expression	25607892
193	76-22-2	SLC1A2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A2 mRNA	affects^cotreatment\|increases^expression	25607892
194	76-22-2	SLC1A3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A3 mRNA	affects^cotreatment\|increases^expression	25607892
195	76-22-2	SLC1A3	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLC1A3 mRNA	affects^cotreatment\|increases^expression	25607892
196	76-22-2	SLC1A6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of SLC1A6 mRNA	affects^cotreatment\|increases^expression	25607892
197	76-22-2	SLIT1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SLIT1 mRNA	affects^cotreatment\|decreases^expression	25607892
198	76-22-2	SLIT1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SLIT1 mRNA	affects^cotreatment\|increases^expression	25607892
199	76-22-2	SPTBN2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SPTBN2 mRNA	affects^cotreatment\|decreases^expression	25607892
200	76-22-2	STMN2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STMN2 mRNA	affects^cotreatment\|increases^expression	25607892
201	76-22-2	STS	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of STS mRNA	affects^cotreatment\|decreases^expression	25607892
202	76-22-2	STS	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of STS mRNA	affects^cotreatment\|decreases^expression	25607892
203	76-22-2	STX1B	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STX1B mRNA	affects^cotreatment\|increases^expression	25607892
204	76-22-2	STXBP1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of STXBP1 mRNA	affects^cotreatment\|increases^expression	25607892
205	76-22-2	STXBP1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of STXBP1 mRNA	affects^cotreatment\|increases^expression	25607892
206	76-22-2	SYNGAP1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SYNGAP1 mRNA	affects^cotreatment\|decreases^expression	25607892
207	76-22-2	SYP	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SYP mRNA	affects^cotreatment\|increases^expression	25607892
208	76-22-2	SYT6	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SYT6 mRNA	affects^cotreatment\|decreases^expression	25607892
209	76-22-2	TBX3	Homo sapiens	enzacamene results in increased expression of TBX3 mRNA	increases^expression	23397585
210	76-22-2	TFF1	Homo sapiens	enzacamene results in increased expression of TFF1 mRNA	increases^expression	16183391
211	76-22-2	TFF1	Homo sapiens	[oxybenzone co-treated with 2,4-dihydroxybenzophenone co-treated with octylmethoxycinnamate co-treated with enzacamene] results in increased expression of TFF1 mRNA	affects^cotreatment\|increases^expression	16183391
212	76-22-2	TGFB1	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TGFB1 mRNA	affects^cotreatment\|decreases^expression	25607892
213	76-22-2	TGOLN2	Homo sapiens	enzacamene results in increased expression of TGOLN2 mRNA	increases^expression	23397585
214	76-22-2	TSC2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of TSC2 mRNA	affects^cotreatment\|increases^expression	25607892
215	76-22-2	TSC2	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of TSC2 mRNA	affects^cotreatment\|increases^expression	25607892
216	76-22-2	TSNAX	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of TSNAX mRNA	affects^cotreatment\|decreases^expression	25607892
217	76-22-2	UNC5A	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5A mRNA	affects^cotreatment\|decreases^expression	25607892
218	76-22-2	UNC5B	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of UNC5B mRNA	affects^cotreatment\|decreases^expression	25607892
219	76-22-2	UNC5C	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of UNC5C mRNA	affects^cotreatment\|increases^expression	25607892
220	76-22-2	UNC5C	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of UNC5C mRNA	affects^cotreatment\|increases^expression	25607892
221	76-22-2	VEGFA	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of VEGFA mRNA	affects^cotreatment\|increases^expression	25607892
222	76-22-2	VLDLR	Rattus norvegicus	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of VLDLR mRNA	affects^cotreatment\|decreases^expression	25607892
223	76-22-2	ZNF676	Homo sapiens	enzacamene results in decreased expression of ZNF676 mRNA	decreases^expression	23397585

Serial No.	Activity Name	Details	References (PubMed)	Other details EPA (U.S)	Clinical Trials (U.S. NIH)
1				76-22-2	Camphor

Plant Variety and Essential oils

Serial No.	Plant Name	Variety Name	Essential Oil
1	French basil, Indian basil, Sweet basil	CIM-Saumya	Ocimum basilicum CIM-Saumya essential oil
2	French basil, Indian basil, Sweet basil	Vikarsudha	Ocimum basilicum vikarsudha essential oil
3	French basil, Indian basil, Sweet basil	CIM-Sharada	Ocimum basilicum CIM-Sharada essential oil
4	French basil, Indian basil, Sweet basil	Kusumohak	Ocimum basilicum Kusumohak essential oil
5	Rosemary	CIM-Hariyali	Rosmarinus officinali CIM-Hariyali essential oil
6	Lavendula angustifolia	Sher-e-Kashmir	Lavandula angustifolia sher-e-Kashmir essential oil
7	Lemongrass	Cauvery	Cymbopogon flexuosus Cauvery essential oil
8	Hook		Cymbopogon microstachys essential oil
9	Hornem		Ocimum ciliatum essential oil
10	Oliveria		Oliveria decumbens essential oil
11	Clarysage		Salvia officinalis essential oil
12	Garden Mint, Pudina	Ganga	Mentha Viridis essential oil
13	Sweet wormwood, Quinghao	CIM-Arogya	Artemisia annua CIM-Arogya essential oil
14	Sweet wormwood, Quinghao	Jeevanraksha	Artemisia annua Jeevanraksha essential oil
15	Lemongrass	Chirharit	Cymbopogon flexuosus Chirharit essential oil
16	Lemongrass	CIMAP-Suwarna	Cymbopogon flexuosus CIMAP-Suwarna essential oil
17	Lemongrass	Krishna	Cymbopogon flexuosus krishna essential oil
18	Lemongrass	T-1	Cymbopogon flexuosus T-1 essential oil
19	Water dropwort		Oenanthe crocata essential oil
20	Water dropwort		Oenanthe crocata essential oil
21	White turmeric		Curcuma zedoaria essential oil
22	Feverfew		Tanacetum parthenium essential oil
23	Sweet violet		Viola odorata essential oil
24	Myrtle		Myrtus communis essential oil
25	Broadleaved lavender, spike lavender or Portuguese lavender		Lavandula latifolia essential oil
26	Common yarrow		Achillea millefolium essential oil
27	Shampoo ginger. Bitter ginger		Zingiber zerumbet essential oil
28	Dill		Anethum graveolens essential oil
29	Artemisia dracunculus		Artemisia dracunculus essential oil
30	Artemisia dracunculus		Artemisia dracunculus essential oil
31	Bushkiller		Cayratia japonica essential oil
32	Bushkiller		Cayratia japonica essential oil
33	Chrysanthemum coronarium		Chrysanthemum indicum essential oil
34	Mums		Chrysanthemum indicum essential oil
35	Wild basil		Clinopodium vulgare essential oil
36	Coriandrum Sativum		Coriandrum sativum essential oil
37	Coriandrum Sativum		Coriandrum sativum essential oil
38	Narrow-leaved turmeric		Curcuma angustifolia essential oil
39	Dracocephalum moldavica		NA
40	Hibiscus surattensis		Hibiscus surattensis essential oil

Print Back

Compound Image

2D Structure

Download

loadClass core.package

loadClass java.lang.String

loadClass core.package

JSmol exec jmolApplet0 start applet null

Jmol JavaScript applet jmolApplet0__6038800214345983__ initializing

Jmol getValue debug null

Jmol getValue logLevel null

Jmol getValue allowjavascript true

AppletRegistry.checkIn(jmolApplet0__6038800214345983__)

nographics false

headless false

vwrOptions:

{ "name":"jmolApplet0","allowJavaScript":true,"applet":true,"documentBase":"https://aromadb.cimapbioinfo.in/web_compound_detail.php?id=CRMOL482","platform":"J.awtjs2d.Platform","fullName":"jmolApplet0__6038800214345983__","codePath":"https://aromadb.cimapbioinfo.in/jsmol/j2s/","display":"jmolApplet0_canvas2d","signedApplet":"true","appletReadyCallback":"Jmol._readyCallback","statusListener":"[J.appletjs.Jmol object]","syncId":"6038800214345983","bgcolor":"#FFFFFF" }

setting document base to "https://aromadb.cimapbioinfo.in/web_compound_detail.php?id=CRMOL482"

Jmol Version: 14.2.15_2015.07.09 2015-07-09 21:14

java.vendor: Java2Script (HTML5)

java.version: 2015-07-07 14:00:27 (JSmol/j2s)

os.name: Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)

Access: ALL

memory: 0.0/0.0

processors available: 1

useCommandThread: false

appletId:jmolApplet0 (signed)

loadClass JS.ScriptManager

Jmol getValue emulate null

defaults = "Jmol"

Jmol getValue boxbgcolor null

Jmol getValue bgcolor #FFFFFF

backgroundColor = "#FFFFFF"

Jmol getValue ANIMFRAMECallback null

Jmol getValue APPLETREADYCallback Jmol._readyCallback

APPLETREADYCallback = "Jmol._readyCallback"

callback set for APPLETREADYCallback Jmol._readyCallback APPLETREADY

Jmol getValue ATOMMOVEDCallback null

Jmol getValue CLICKCallback null

Jmol getValue DRAGDROPCallback null

Jmol getValue ECHOCallback null

Jmol getValue ERRORCallback null

Jmol getValue EVALCallback null

Jmol getValue HOVERCallback null

Jmol getValue IMAGECallback null

Jmol getValue LOADSTRUCTCallback null

Jmol getValue MEASURECallback null

Jmol getValue MESSAGECallback null

Jmol getValue MINIMIZATIONCallback null

Jmol getValue SERVICECallback null

Jmol getValue PICKCallback null

Jmol getValue RESIZECallback null

Jmol getValue SCRIPTCallback null

Jmol getValue SYNCCallback null

Jmol getValue STRUCTUREMODIFIEDCallback null

Jmol getValue doTranslate null

language=en_US

Jmol getValue popupMenu null

Jmol getValue script null

Jmol getValue loadInline null

Jmol getValue load null

Jmol applet jmolApplet0__6038800214345983__ ready

script 1 started

antialiasDisplay = true

FileManager.getAtomSetCollectionFromFile(admin/images/Camphor.sdf)

FileManager opening 1 https://aromadb.cimapbioinfo.in/admin/images/Camphor.sdf

The Resolver thinks Mol

2537

DSViewer 3D 0

Time for openFile(admin/images/Camphor.sdf): 673 ms

reading 27 atoms

ModelSet: haveSymmetry:false haveUnitcells:false haveFractionalCoord:false

1 model in this collection. Use getProperty "modelInfo" or getProperty "auxiliaryInfo" to inspect them.

Default Van der Waals type for model set to Babel

27 atoms created

ModelSet: not autobonding; use forceAutobond=true to force automatic bond creation

null

Script completed

Jmol script terminated

Download Sdf File Download PDB File Download MOL File

View Similar Structures (External DB)

AromaDb: A Database of Plant's Aroma Molecules

AROMA: A Database of Plant's Aroma Molecules